PFA

Revenue declinedNet loss reportedEBITDA margin compressionResults View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-8.3%Reaction day

₹104.00

prior close

—

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.1%-8.2% vs market

Medical Equipment & Supplies peers, median of 13sector+0.0%-8.3% vs sector

On the reaction day the stock moved 8.2 pts less than Nifty Microcap 250 and 8.3 pts less than its Medical Equipment & Supplies peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

—

10m

—

15m

—

30m

—

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-8.3-0.1-8.2+0.0-8.3

Next day

-0.2+0.5-0.7-2.0+1.8

—-0.3—-3.2—

-3.8-0.5-3.4-4.0+0.1

+1.8-0.8+2.6-4.3+6.1

-7.7-2.3-5.4-5.2-2.5

+6.8-2.8+9.6-7.2+14.0

15d

-3.5-4.9+1.4-4.0+0.5

-6.4-4.7-1.7-3.8-2.6

-10.4-7.7-2.6-15.1+4.8

-5.8-7.8+2.1-23.7+17.9

UpDownMarket · Nifty Microcap 250Sector · Medical Equipment & Supplies peers, median of 13Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Centenial Surgical Suture Ltd submitted its Q2 and H1 FY26 (ended September 30, 2025) unaudited standalone results alongside a Limited Review Report from its auditor. Revenue from operations came in at Rs 1,345.50 lakhs for the quarter, down from Rs 1,427.24 lakhs in Q2 FY25, while half-year revenue stood at Rs 2,639.11 lakhs versus Rs 2,800.97 lakhs a year ago. The company slipped into a loss before tax of Rs 1.20 lakhs in Q2 FY26 against a profit of Rs 16.91 lakhs last year, and H1 FY26 posted a small loss of Rs 5.11 lakhs against a profit of Rs 56.75 lakhs in H1 FY25. The full year FY25 had closed with a much larger loss of Rs 161.78 lakhs. The auditor issued an unmodified (clean) Limited Review Report on the results.

Likely market impact

Revenue is declining year-on-year and the company has swung from profit to loss, signalling continued pressure on the medical devices business. Shareholders should note weakening top-line and the persistence of losses, which may weigh on the stock in the short term.